
    terminated 25sep17 due to insufficient efficacy. not due to safety reasons.
  
['parkinson disease']
['placebo', 'pf-06649751 low dose (1 mg qd)', 'pf-06649751 middle dose 1 (3 mg qd)', 'pf-06649751 middle dose 2 (7 mg qd)', 'pf-06649751 high dose (15 mg qd)']

        Inclusion Criteria:

          -  Females of non-childbearing potential and/or male subjects between the ages of 40 and
             85 years, inclusive.

          -  Clinical diagnosis of Parkinson's disease.

          -  Able to refrain from any Parkinson's disease medication not permitted by the protocol.

        Exclusion Criteria:

          -  Female of childbearing potential

          -  History or presence of atypical Parkinsonian syndrome.

          -  History of surgical intervention for Parkinson's disease.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Any condition possibly affecting drug absorption.

          -  Participation in other studies involving investigational drug(s), or treatment with
             any investigational drug within 30 days.
      